Conditions: Neoplasms
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 58
Healthy volunteers: no

Brief summary:
The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours. Part B will involve expansion of the MTD to 3 cohorts including non-small cell lung cancer squamous histology, recurrent/ metastatic squamous cell carcinoma of head and neck and other advanced solid tumours (except sarcomas).

Detailed description:

Arms:
arm 1: Patients to receive afatinib once daily plus weekly cetuximab infusion

Interventions: intervention 1: Cetuximab( erbitux®) intervention 2: Afatinib
Intervention descriptions: intervention 1: once per week intervention 2: once per day

Protocol document: